These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Application of ImmunoScore Model for the Differentiation between Active Tuberculosis and Latent Tuberculosis Infection as Well as Monitoring Anti-tuberculosis Therapy. Zhou Y; Du J; Hou HY; Lu YF; Yu J; Mao LY; Wang F; Sun ZY Front Cell Infect Microbiol; 2017; 7():457. PubMed ID: 29164066 [TBL] [Abstract][Full Text] [Related]
4. Biomarkers on patient T cells diagnose active tuberculosis and monitor treatment response. Adekambi T; Ibegbu CC; Cagle S; Kalokhe AS; Wang YF; Hu Y; Day CL; Ray SM; Rengarajan J J Clin Invest; 2015 May; 125(5):1827-38. PubMed ID: 25822019 [TBL] [Abstract][Full Text] [Related]
5. Biomarkers for discrimination between latent tuberculosis infection and active tuberculosis disease. Won EJ; Choi JH; Cho YN; Jin HM; Kee HJ; Park YW; Kwon YS; Kee SJ J Infect; 2017 Mar; 74(3):281-293. PubMed ID: 27871809 [TBL] [Abstract][Full Text] [Related]
7. Microarray-based selection of a serum biomarker panel that can discriminate between latent and active pulmonary TB. Li Z; Hu J; Liu P; Cui D; Di H; Wu S Sci Rep; 2021 Jul; 11(1):14516. PubMed ID: 34267288 [TBL] [Abstract][Full Text] [Related]
8. Chemokines additional to IFN-γ can be used to differentiate among Mycobacterium tuberculosis infection possibilities and provide evidence of an early clearance phenotype. Nonghanphithak D; Reechaipichitkul W; Namwat W; Naranbhai V; Faksri K Tuberculosis (Edinb); 2017 Jul; 105():28-34. PubMed ID: 28610785 [TBL] [Abstract][Full Text] [Related]
9. Detection of Mycobacterium tuberculosis peptides in the exosomes of patients with active and latent M. tuberculosis infection using MRM-MS. Kruh-Garcia NA; Wolfe LM; Chaisson LH; Worodria WO; Nahid P; Schorey JS; Davis JL; Dobos KM PLoS One; 2014; 9(7):e103811. PubMed ID: 25080351 [TBL] [Abstract][Full Text] [Related]
10. Phenotypic Changes on Mycobacterium Tuberculosis-Specific CD4 T Cells as Surrogate Markers for Tuberculosis Treatment Efficacy. Ahmed MIM; Ntinginya NE; Kibiki G; Mtafya BA; Semvua H; Mpagama S; Mtabho C; Saathoff E; Held K; Loose R; Kroidl I; Chachage M; von Both U; Haule A; Mekota AM; Boeree MJ; Gillespie SH; Hoelscher M; Heinrich N; Geldmacher C Front Immunol; 2018; 9():2247. PubMed ID: 30323818 [No Abstract] [Full Text] [Related]
11. Screening of Serum Biomarkers for Distinguishing between Latent and Active Tuberculosis Using Proteome Microarray. Cao SH; Chen YQ; Sun Y; Liu Y; Zheng SH; Zhang ZG; Li CY Biomed Environ Sci; 2018 Jul; 31(7):515-526. PubMed ID: 30145986 [TBL] [Abstract][Full Text] [Related]
12. A combination of iron metabolism indexes and tuberculosis-specific antigen/phytohemagglutinin ratio for distinguishing active tuberculosis from latent tuberculosis infection. Luo Y; Xue Y; Lin Q; Tang G; Yuan X; Mao L; Song H; Wang F; Sun Z Int J Infect Dis; 2020 Aug; 97():190-196. PubMed ID: 32497795 [TBL] [Abstract][Full Text] [Related]
13. Potential of DosR and Rpf antigens from Mycobacterium tuberculosis to discriminate between latent and active tuberculosis in a tuberculosis endemic population of Medellin Colombia. Arroyo L; Marín D; Franken KLMC; Ottenhoff THM; Barrera LF BMC Infect Dis; 2018 Jan; 18(1):26. PubMed ID: 29310595 [TBL] [Abstract][Full Text] [Related]
14. Multiplex analysis of plasma cytokines/chemokines showing different immune responses in active TB patients, latent TB infection and healthy participants. Yao X; Liu Y; Liu Y; Liu W; Ye Z; Zheng C; Ge S Tuberculosis (Edinb); 2017 Dec; 107():88-94. PubMed ID: 29050777 [TBL] [Abstract][Full Text] [Related]
15. Characterization of plasma proteins in children of different Li J; Sun L; Xu F; Xiao J; Jiao W; Qi H; Shen C; Shen A Oncotarget; 2017 Nov; 8(61):103290-103301. PubMed ID: 29262562 [TBL] [Abstract][Full Text] [Related]
16. Chang SY; Chen ML; Lee MR; Liang YC; Lu TP; Wang JY; Yan BS Dis Markers; 2018; 2018():4687380. PubMed ID: 30627224 [TBL] [Abstract][Full Text] [Related]
17. Novel serological biomarker panel using protein microarray can distinguish active TB from latent TB infection. Li J; Wang Y; Yan L; Zhang C; He Y; Zou J; Zhou Y; Zhong C; Zhang X Microbes Infect; 2022; 24(8):105002. PubMed ID: 35598729 [TBL] [Abstract][Full Text] [Related]
18. The effect of HIV coinfection, HAART and TB treatment on cytokine/chemokine responses to Mycobacterium tuberculosis (Mtb) antigens in active TB patients and latently Mtb infected individuals. Kassa D; de Jager W; Gebremichael G; Alemayehu Y; Ran L; Fransen J; Wolday D; Messele T; Tegbaru B; Ottenhoff TH; van Baarle D Tuberculosis (Edinb); 2016 Jan; 96():131-40. PubMed ID: 26631832 [TBL] [Abstract][Full Text] [Related]
19. Differential T cell responses against DosR-associated antigen Rv2028c in BCG-vaccinated populations with tuberculosis infection. Zhao HM; Du R; Li CL; Ji P; Li HC; Wu K; Hu Z; Lu SH; Lowrie DB; Fan XY J Infect; 2019 Apr; 78(4):275-280. PubMed ID: 30528871 [TBL] [Abstract][Full Text] [Related]
20. Serum exosome tRFs as a promising biomarker for active tuberculosis and latent tuberculosis infection. Xi X; Wang B; Zhang R; Ling C J Microbiol Methods; 2024 Jul; 222():106944. PubMed ID: 38705210 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]